secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001437749-25-026356
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia and CART-Tech enter exclusive pact for Heart3D Fusion Imaging
-----------------------------------------------------------------------

- Exclusive development/commercialization agreement for Heart3D Fusion Imaging, enhancing 2D x-rays with 3D anatomical models.
- BioCardia gets exclusive global rights for biotherapeutic delivery and US rights for cardiac biopsy distribution.
- Management estimates $100M annual revenue potential from Heart3D if single large-market biologic becomes standard of care.
- Cross-licensing: BioCardia licenses CART-Tech IP for biotherapeutic intervention; CART-Tech licenses BioCardia IP for CRT.
- Heart3D initially sold as research tool for preclinical studies, later for clinical practice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925026356/0001437749-25-026356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925026356/bcda20250812_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-026356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer